A single intravenous dose of an experimental CRISPR-based therapy reduced cholesterol and harmful triglyceride levels by roughly half in a small early study, researchers reported. The trial involved 15 volunteers and found the one-time infusion appeared safe and produced substantial, durable reductions in blood lipids in the months observed.
Investigators, including preventive cardiologists from the Cleveland Clinic, presented the results at the American Heart Association’s annual meeting and published the findings in The New England Journal of Medicine. The drug is designed to travel to the liver and disable a gene called ANGPTL3, which plays a role in producing cholesterol and triglycerides. By “knocking out” that gene, the therapy aims to halt its function and lower lipid levels without requiring daily pills.
“Rather than a lifetime worth of medicine, we have the potential to give people a cure,” said Dr. Luke Laffin, who helped conduct the study. Dr. Steven Nissen, another investigator, described the treatment as cutting the gene so it no longer works.
Industry leaders developing the approach say it could reach millions of people worldwide if larger trials confirm the benefit. Samarth Kulkarni, CEO of the company sponsoring the study, said the strategy “could potentially impact millions of people around the world.” Researchers at other companies are pursuing similar CRISPR-based therapies; early clinical data from multiple groups adds to evidence that the concept can work.
Experts not involved in the trial praised the progress but urged caution. Dr. Eric Topol noted that gene-editing is currently expensive and that long-term safety remains uncertain, so the vision of a cheap, one-time cure is still speculative. Dr. Kiran Musunuru called the results “a step in the right direction” and said more research is needed to show that gene editing actually prevents heart attacks and strokes.
Those safety and proof-of-benefit questions matter especially because most people considered for cholesterol-lowering therapy are otherwise healthy. Regulators and physicians will demand a high safety standard before using permanent gene edits as a preventive intervention.
The potential advantages are clear: millions of people take daily medications such as statins to lower their risk of heart attack and stroke, and poor long-term adherence is a major reason treatments fail. A single, durable intervention could eliminate the adherence problem if it proves safe, effective and affordable.
Costs remain an open question. Other gene therapies have been priced in the millions per patient, and neither company developing these CRISPR lipid-lowering therapies has announced likely pricing. Researchers are planning larger and longer trials to assess whether a one-time gene-editing infusion can safely protect people from cardiovascular events over years.
Fyodor Urnov, who studies gene editing, said the accumulating clinical data are encouraging and that a CRISPR medicine that reduces heart attacks would be an extraordinary achievement. For now, the new study represents promising early evidence but not yet a proven, widely available cure.